利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.013 秒)

    Diabetes Biomarkers
    6.
    发明公开
    Diabetes Biomarkers 审中-公开

    公开(公告)号：US20230333094A1

    公开(公告)日：2023-10-19

    申请号：US18140214

    申请日：2023-04-27

    申请人： Phaim Pharma Ltd.

    发明人： Tihamer ORBAN

    IPC分类号： G01N33/50 ,  G01N33/564 ,  G01N33/569

    CPC分类号： G01N33/5094 ,  G01N33/564 ,  G01N33/56972 ,  G01N2800/042 ,  G01N2800/52

    摘要： A new markers for insulin production decline in Type 1 diabetes has been found in the ratio the CD4 naïve (CD45RO−CD62L+) to central memory (CD45RO+CD62L+) and in the level of CD4 central memory T-cell subpopulations. A method of diagnosing autoimmunity and its progressiveness, more specifically diabetes, pre-diabetes, a susceptibility to diabetes mellitus, or the level of effectiveness of therapy/intervention modality for one or more of such conditions in a subject can be conducted by determining level of CD4 naïve (CD45RO−CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject; determining level of CD4 central memory (CD45RO+CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject, and quantitatively relating the levels of the CD4 naïve and central memory T-cells, wherein a low ratio of CD4 naïve T-cells to CD4 central memory T-cells and/or high CD4 central memory T-cell indicates autoimmunity, a susceptibility to autoimmunity, diabetes, pre-diabetes, a susceptibility to diabetes mellitus or ineffectiveness of a treatment for one or more of such conditions.